<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375502</url>
  </required_header>
  <id_info>
    <org_study_id>MG1111_P2/3</org_study_id>
    <nct_id>NCT03375502</nct_id>
  </id_info>
  <brief_title>A Study of MG1111 in Healthy Children</brief_title>
  <official_title>A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <brief_summary>
    <textblock>
      To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus
      comparator
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieved seroconversion</measure>
    <time_frame>42 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer(GMT) measured by the FAMA assay</measure>
    <time_frame>At day 0 and Day 42 post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer(GMT) measured by gpELISA</measure>
    <time_frame>At day 0 and Day 42 post-vaccination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Local/systemic solicited AEs [Safety]</measure>
    <time_frame>during the first 7 days after administration of IP</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Unsolicited AEs [Safety]</measure>
    <time_frame>Until Day 42 after administration of IP</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Serious adverse events [Safety]</measure>
    <time_frame>Until 6 months after administration of IP</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">828</enrollment>
  <condition>Healthy Children</condition>
  <arm_group>
    <arm_group_label>MG1111(Varicella vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator(Varicella vaccine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varicella Vaccine</intervention_name>
    <description>The subject will receive investigational product or comparator.</description>
    <arm_group_label>MG1111(Varicella vaccine)</arm_group_label>
    <arm_group_label>Comparator(Varicella vaccine)</arm_group_label>
    <other_name>vaccination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy children aged 12 months to 12 years.

          -  Subjects or parent/legal representative willing to provide written informed consent
             and able to comply with the requirements for the study - Subject able to attend all
             scheduled visits and to comply with all study procedures

          -  Negative history of Varicella and varicella vaccine

          -  Subject in good health, based on medical history and physical examination

        Exclusion Criteria:

          -  Subjects who have a history of Varicella or administration of varicella vaccine

          -  Subjects who have ahd an acute febrile episode at some time during the 72 hours before
             administration of investigational product or those who had any symptom suspected to be
             allergy including systemic rash.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GreenCross</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>The catholic university of Korea, Seoul st. mary's hospital</name>
      <address>
        <city>Banpo-dong</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JinHan Kang, MD</last_name>
      <phone>82-2-1588-1511</phone>
      <email>kjhan@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

